Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva PharmafiledCriticalTeva Pharma
Publication of AR094809A1publicationCriticalpatent/AR094809A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Un método para tratar un sujeto humano afectado por una forma progresiva de esclerosis múltiple, que comprende administrar periódicamente al sujeto humano una cantidad de laquinimod eficaz para tratar al sujeto humano. Laquinimod para usar en el tratamiento de un sujeto humano afectado por una forma progresiva de esclerosis múltiple. Composiciones farmacéuticas y envases que comprenden una cantidad eficaz de laquinimod para tratar una forma progresiva de esclerosis múltiple.A method of treating a human subject affected by a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subject. Laquinimod for use in the treatment of a human subject affected by a progressive form of multiple sclerosis. Pharmaceutical compositions and packages comprising an effective amount of laquinimod to treat a progressive form of multiple sclerosis.
ARP140100492A2013-02-152014-02-14
TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
AR094809A1
(en)